New studies suggest that GLP-1 drugs may be linked to a higher risk of fracture, osteoporosis, and gout. However, some research indicates that certain GLP-1 medications, such as semaglutide, may actually help protect bone health or lower the risk of bone fractures in some individuals, particularly those with type 2 diabetes. The relationship between GLP-1 drugs and bone health appears to be complex and may vary depending on factors such as the presence of diabetes.